RICHMOND, British Columbia, Dec. 8, 2011 (GLOBE NEWSWIRE) -- BioCurex Inc. (OTCBB:BOCX) announced today that its wholly owned subsidiary, OncoPet™ Diagnostics, Inc., has executed an agreement for the distribution of the OncoPet Sample Collection Kit for canine cancer diagnosis with Butler Schein™ Animal Health. Butler Schein Animal Health, a division of Henry Schein (Nasdaq:HSIC), is the leading companion animal health distribution company in the U.S.
According to the agreement, Butler Schein is allowed to purchase the OncoPet Sample Collection Kit from OncoPet Diagnostics to resell to their vast network of veterinary professionals in the United States. The Company has sent Webster Veterinary notice of termination of its previous distribution agreement.
"We are extremely satisfied to have completed a definitive distribution agreement for sales of the OncoPet Sample Collection Kit with Butler Schein," stated Dr. Paul D. Slowey, President of BioCurex. "With the largest animal health distribution company in the U.S. now under agreement with OncoPet, we are confident that our products and services will be comprehensively represented to animal health professionals throughout the largest veterinary market in the world.
Dr. Ricardo Moro, OncoPet's President and BioCurex's CEO added, "It is important to stress the significance of this agreement because the largest distributor of veterinary products in the U.S. knows what sells well and how to make money with the products they carry. Their confidence in the OncoPet RECAF test is a huge endorsement and a clear indication of its commercial potential. The sales force of this company is in the hundreds and our facilities are ready to process any orders resulting from their efforts.
About Butler Schein
Butler Schein Animal Health, a division of Henry Schein, is the leading companion animal health distribution company in the U.S.
Headquartered in Dublin, Ohio, the company employs approximately 900 team members, including 300 field sales representatives and 200 telesales and customer support representatives. With 17 strategically positioned, state-of-the-art distribution facilities and 12 inside sales centers nationwide, Butler-Schein maintains a greater than 98 percent order-fill ratio, accomplishing its mission of providing the right product, at the right place and at the right time.
Partnering with over 400 of the leading animal health manufacturers in the world, Butler-Schein is positioned to bring the broadest selection of veterinary products and strategic business solutions to over 26,000 veterinary professionals nationwide.
About BioCurex, Inc.
BioCurex, Inc. is a biotechnology company that is developing products based on patented and proprietary technology in the area of cancer diagnostics. The technology identifies a universal cancer marker known as RECAF.
RECAF is a molecule that is present on cancer cells but not detected in significant levels on healthy cells or benign tumor cells. It is the receptor for alpha-fetoprotein and is classified as an oncofetal antigen due to its presence on both fetal and malignant tissues. This characteristic makes RECAF a more accurate indicator of cancer than most current tumor markers.
BioCurex is commercializing its technology through licensing arrangements with companies that develop and market diagnostic tests for the large automated clinical laboratory setting, through development and marketing of non-automated clinical laboratory tests, through development of rapid, point-of-care test formats, and through marketing of its OncoPet RECAF test for cancer in companion animals.
BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories (NYSE:ABT) and with Alere (NYSE:ALR), formerly Inverness Medical Innovations (NYSE:IMA).
For further information on these agreements visit:
http://sec.gov/Archives/edgar/data/1092562/000100487808000117/sb2amnd4s1april08.txt.
For more information about the Company, please visit www.BioCurex.com.
For more information about OncoPet Diagnostics Inc., please visit: www.OncoPetDiagnostics.com.
Forward-Looking Statements
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements, such as forecasts of future sales, involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.